Altogether, our data indicate that AMPK activation is a metabolic vulnerability in SLC6A14-deficient cells that can be exploited as a therapeutic approach to drive unbalanced metabolism in starved tumor cells. This evidence concerns the gene PRKAA1 and neoplasm.